Assetmark, Inc Repligen Corp Transaction History

Assetmark, Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$114.17 - $185.35 $238,957 - $387,937	-2,093 Reduced 99.9%	2 $0
Q3 2023 Oct 27, 2023	SELL	$138.78 - $176.51 $413,425 - $525,823	-2,979 Reduced 58.71%	2,095 $333,000
Q2 2023 Aug 11, 2023	SELL	$138.42 - $180.31 $8,720 - $11,359	-63 Reduced 1.23%	5,074 $717,000
Q1 2023 May 05, 2023	SELL	$154.26 - $198.1 $4,473 - $5,744	-29 Reduced 0.56%	5,137 $864,000
Q4 2022 Feb 10, 2023	BUY	$162.42 - $220.56 $76,987 - $104,545	474 Added 10.1%	5,166 $874,000
Q3 2022 Nov 01, 2022	BUY	$160.42 - $256.21 $58,713 - $93,772	366 Added 8.46%	4,692 $878,000
Q2 2022 Aug 03, 2022	BUY	$140.68 - $188.02 $99,038 - $132,366	704 Added 19.44%	4,326 $703,000
Q1 2022 May 13, 2022	BUY	$161.19 - $257.96 $301,425 - $482,385	1,870 Added 106.74%	3,622 $681,000
Q4 2021 Feb 14, 2022	BUY	$247.59 - $304.47 $391,687 - $481,671	1,582 Added 930.59%	1,752 $464,000
Q3 2021 Nov 12, 2021	BUY	$194.77 - $324.21 $33,110 - $55,115	170 New	170 $49,000
Q2 2021 Aug 16, 2021	SELL	$165.87 - $220.95 $2,819 - $3,756	-17 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$180.37 - $226.26 $180 - $226	-1 Reduced 5.56%	17 $3,000
Q3 2020 Nov 13, 2020	SELL	$122.51 - $158.27 $245 - $316	-2 Reduced 10.0%	18 $3,000
Q2 2020 Aug 11, 2020	SELL	$94.33 - $140.48 $188 - $280	-2 Reduced 9.09%	20 $2,000
Q1 2020 May 12, 2020	BUY	$84.96 - $109.14 $1,869 - $2,401	22 New	22 $2,000
Q1 2018 May 16, 2018	SELL	$30.92 - $37.27 $401 - $484	-13 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$32.53 - $38.92 $422 - $505	13	13 $0

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.